PHVS — Pharvaris N.V. stock price, charts and financials

NASDAQ·Healthcare·Biotechnology·Switzerland

Latest market price

36.37

-1.63-4.29%

Overview Short InterestFilings

PHVSQT79Pharvaris N.V.·NASDAQ

Overview Short InterestFilings

36.37-4.29%

News

Down 4.3% — Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock (defenseworld.net).

Medium confidence

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

CLDX-1.90%$38.24 BEAM+1.14%$24.95 VRDN+0.32%$22.00 MLYS+0.14%$28.02 NAMS+2.55%$22.49 NRIX-0.24%$25.44 VERA-0.79%$34.00 HRMY-1.68%$42.02

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	1.82%	Shs Outstand	69.88M	Perf Week	-4.34%

Market Cap	2.54B	Forward P/E	-	EPS next Y	-3.11	Insider Trans	-42.91%	Shs Float	33.19M	Perf Month	0.28%

Enterprise Value	2.18B	PEG	-	EPS next Q	-0.94	Inst Own	-	Short Float	3.09%	Perf Quarter	10.88%

Income	-198.00M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	4.15	Perf Half Y	39.19%

Sales	0.00	P/B	7.41	EPS next Y	3.27%	ROA	-52.20%	Short Interest	2.16M	Perf YTD	31.06%

Book/sh	4.91	P/C	7.00	EPS next 5Y	-	ROE	-61.24%	52W High	43.25 -15.91%	Perf Year	51.04%

Cash/sh	5.19	P/FCF	-	EPS past 3/5Y	-	ROIC	-60.72%	52W Low	20.65 76.13%	Perf 3Y	76.47%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	4.95% 5.20%	Perf 5Y	84.06%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	-17.40%	Oper. Margin	0.00%	ATR (14)	2.06	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	11.94	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	49.49	Recom	2.07

Dividend Gr. 3/5Y	-	Current Ratio	11.94	EPS Q/Q	8.99%	SMA20	-1.13%	Beta	-2.60	Target Price	62.00

Payout	0.00%	Debt/Eq	0.00	Sales Q/Q	-	SMA50	2.83%	Rel Volume	0.80	Prev Close	38.00

Employees	148	LT Debt/Eq	0.00	Earnings	Nov 11	SMA200	20.91%	Avg Volume	722.09K	Price	36.37

IPO Date	Feb 04, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-6.75% -	Net Debt/EBITDA	1.84	Volume	579,849	Change	-4.29%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-14-26	Reiterated	Cantor Fitzgerald	Overweight	$65
Sep-10-26	Reiterated	Guggenheim	Buy	$40 → $44
Sep-09-26	Reiterated	Rosenblatt Securities		$60
Sep-09-26	Reiterated	UBS		$75 → $79
Sep-09-26	Reiterated	RBC Capital	Outperform	$52 → $62
Sep-09-26	Reiterated	Wedbush	Outperform	$27 → $50
Sep-09-26	Reiterated	Morgan Stanley	Overweight	$46 → $62
Sep-09-26	Reiterated	Leerink Partners	Outperform	$38 → $65
Sep-09-26	Reiterated	Wells Fargo	Overweight	$55 → $65
Sep-08-26	Reiterated	Oppenheimer	Outperform	$50 → $75

Latest News· Times ET

Sep-16-26

Sep-16-2601:10AM

Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stockdefenseworld.net

12:37AM

Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLCdefenseworld.net

Sep-15-26

Sep-15-2601:41PM

Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

06:51AM

PHVS Stock Rises 10% in a Month: What Is Driving the Rally?zacks.com

Sep-09-26

Sep-09-2610:18AM

Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Winseekingalpha.com

Sep-08-26

Sep-08-2609:45AM

Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema TranscriptSeekingAlpha

03:52AM

Pharvaris' genetic disorder drug meets main goal in late-stage trialreuters.com

02:50AM

Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacksglobenewswire.com

Sep-06-26

Sep-06-2604:51AM

Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow Itmarketbeat.com

Sep-03-26

Sep-03-2602:50AM

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026globenewswire.com

Sep-02-26

Sep-02-2611:50PM

BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVSdefenseworld.net

Aug-26-26

Aug-26-2612:13AM

5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVSdefenseworld.net

Aug-13-26

Aug-13-2607:37AM

RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52Benzinga

Aug-12-26

Aug-12-2602:53AM

Pharvaris Q2 EPS $(0.81) Misses $(0.74) EstimateBenzinga

02:50AM

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Updateglobenewswire.com

Company

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	0	0	—	—	—	—	—
Gross Profit	0	0	0	—	—	—	—	—
Selling, General and Administrative Excl. Other	51	51	34	—	—	—	—	—
Research and Development	140	107	71	—	—	—	—	—
Other Operating Expense	1	0	0	—	—	—	—	—
Operating Income	-192	-158	-105	—	—	—	—	—
Interest Expense	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	-4	14	-3	—	—	—	—	—
Net Income Before Taxes	-196	-143	-108	—	—	—	—	—
Income Taxes	2	2	1	—	—	—	—	—
Consolidated Net Income	-198	-145	-109	—	—	—	—	—
Net Income From Continuing Operations	-198	-145	-109	—	—	—	—	—
Net Income	-198	-145	-109	—	—	—	—	—
EPS (Recurring)	-3.35	-2.68	-2.84	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-3.35	-2.68	-2.84	—	—	—	—	—
EPS (Diluted)	-3.35	-2.68	-2.84	—	—	—	—	—
EBITDA	-195	-158	-108	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—
Shares Outstanding	59	54	38	—	—	—	—	—
Market Capitalization	1,637	1,035	1,066	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Abele Stefan Andreas	Chief Technical Ops Officer	Sep 15 '26	Sale	38.17	46,400	1,771,126	39,068	Sep 17
Abele Stefan Andreas	Chief Technical Ops Officer	Sep 15 '26	Option Exercise	16.40	45,000	738,000	85,468	Sep 17
Glassman Robert	Director	Sep 15 '26	Option Exercise	22.31	8,667	193,361	19,167	Sep 17
Glassman Robert	Director	Sep 15 '26	Sale	38.27	8,667	331,716	10,500	Sep 17
Souverijns Wim	Chief Commercial Officer	Sep 15 '26	Sale	38.99	6,090	237,449	39,021	Sep 16
Souverijns Wim	Chief Commercial Officer	Sep 14 '26	Sale	39.31	20,000	786,126	45,111	Sep 16
Souverijns Wim	Chief Commercial Officer	Sep 14 '26	Option Exercise	17.43	20,000	348,600	65,111	Sep 16
Modig Berndt	Chief Executive Officer	Sep 14 '26	Sale	39.40	2,291	90,276	128,334	Sep 15
Lu Peng	President	Sep 11 '26	Option Exercise	2.59	15,000	38,850	80,179	Sep 15
Lu Peng	President	Sep 11 '26	Sale	40.13	15,000	601,947	65,179	Sep 15
Lesage Anne	Chief Early Development	Sep 10 '26	Option Exercise	8.05	38,000	305,900	86,450	Sep 14
Lesage Anne	Chief Early Development	Sep 10 '26	Sale	38.30	30,000	1,149,084	56,450	Sep 14
Glassman Robert	Director	Sep 09 '26	Sale	37.55	8,000	300,396	10,500	Sep 11
Glassman Robert	Director	Sep 09 '26	Option Exercise	20.00	8,000	160,000	18,500	Sep 11
Lu Peng	President	Sep 08 '26	Option Exercise	2.59	15,000	38,850	80,179	Sep 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.